AEterna Zentaris Inc. (AEZS)

[~ Blue ~]

another news! AEZS short term price target 1.5 dollars!


AEterna Zentaris Inc. (NASDAQ:AEZS) Price Target Update
September 10, 2015 ·

AEterna Zentaris Inc. (NASDAQ:AEZS): 2 Analyst have given the stock of AEterna Zentaris Inc. (NASDAQ:AEZS) a near short term price target of $1.5. The standard deviation reading, which is a measure by which the stock price is expected to swing away from the mean estimate, is at $0.71. The higher price target estimate is at $2 while the lower price estimates are fixed at $1.

Research firm Zacks has rated AEterna Zentaris Inc. (NASDAQ:AEZS) and has ranked it at 2, indicating that for the short term the shares are a buy. 2 Wall Street analysts have given the company an average rating of 1. Strong buy was given by 2 Wall Street Analysts.

Aeterna Zentaris Inc. has lost 25.45% in the last five trading days and dropped 59.36% in the last 4 weeks. Aeterna Zentaris Inc. has dropped 77.57% during the last 3-month period . Year-to-Date the stock performance stands at -89.07%.

Several analysts have commented on the company rating. In a research note released to the investors, HC Wainwright upgrades its rating on AEterna Zentaris Inc. (NASDAQ:AEZS). Investors must note that the brokerage house has a Buy rating on the shares of the company. Previously, the company had a rating of Neutral. The Brokerage Firm announces its price target at $1.25 per share on the company. The rating by the firm was issued on April 14, 2015.

AEterna Zentaris Inc. (NASDAQ:AEZS) witnessed a decline in the market cap on Wednesday as its shares dropped 16.22% or 0.0127 points. After the session commenced at $0.08, the stock reached the higher end at $0.0813 while it hit a low of $0.065. With the volume soaring to 21,800,909 shares, the last trade was called at $0.0656. The company has a 52-week high of $1.46. The company has a market cap of $6.3 million and there are 95,895,000 shares in outstanding. The 52-week low of the share price is $0.075.

The company shares have dropped -94.07% from its 1 Year high price. On Sep 16, 2014, the shares registered one year high at $1.46 and the one year low was seen on Sep 8, 2015. The 50-Day Moving Average price is $0.14 and the 200 Day Moving Average price is recorded at $0.37.

Aeterna Zentaris Inc. is a late-stage drug development company specialized in oncology and endocrine therapy. The Companys pipeline encompasses compounds at all stages of development, from drug discovery through to marketed products. The development priorities in oncology are the completion of Phase 3 trials with perifosine in colorectal cancer (CRC) and in multiple myeloma (MM), as well as the further advancement of AEZS-108, for which it has completed a Phase 2 trial in advanced endometrial and advanced ovarian cancer. Its pipeline also encompasses other earlier-stage programs in oncology. AEZS-112, which is an oral anticancer agent, which includes three mechanisms of action (tubulin, topoisomerase II and angiogenesis inhibition) has completed a Phase 1 trial in advanced solid tumors and lymphoma.

http://www.moneyflowindex.org/aeterna-zentaris-inc-nasdaqaezs-price-target-update/3124216/